Musings from The Power List: John Maher
By John Maher
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
False
Advertisement
Technology & Manufacturing
Why Cell Therapy Needs a Digital Backbone
August 13, 2026
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
8 min read
Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?
August 12, 2026
NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients
11 min read
Building Commercial Readiness in Advanced Therapies
August 10, 2026
Why early process development, analytical planning, and tech transfer can shape the future of cell and gene therapy manufacturing
5 min read
Moving Glycosylation Control Upstream
August 6, 2026
Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.
7 min read
What Did ASCO 2026 Reveal About the Future of Oncology?
By James Strachan
August 6, 2026
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
8 min read
2026 Innovation Awards: Nominate Now
July 31, 2026
Nominations are now open for The Medicine Maker 2026 Innovation Awards, celebrating the latest technologies for drug development and manufacturing
1 min read
Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks
July 23, 2026
Mission Bio’s Mike Molnar explains how single-cell multiomics could improve vector copy number analysis, product characterization, and safety assessment in CAR T development
5 min read
Roving Reporter Asks: How Close Are We to Making CGT Production More Scalable and Repeatable?
July 20, 2026
IBTV speaks with industry leaders at Meeting on the Med 2026 to explore how automation, digitization, and new manufacturing models could make cell and gene therapy production more reproducible, efficient, and accessible
1 min read
Biopharma Vital Signs – Part 5: Capabilities for a Changing Landscape
July 17, 2026
Experts discuss the capabilities companies need to make drug development faster, more flexible, and more resilient – from integrated development and manufacturing flexibility to digital tools, supply chain strategy, and sharper decision-mak...
13 min read
